Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.72 |
| ▸ | APP | P05067 | 3/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | CA3 | P07451 | 2/20 | 0.64 |
| ▸ | CA4 | P22748 | 2/20 | 0.64 |
| ▸ | CA6 | P23280 | 2/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (E)-3,4'-Stilbendiol SCHEMBL720092 | 1.00 | LCK (0.72) | LCKAPPCA12CA1CA2 | |
| (E)-3,4'-Stilbendiol SCHEMBL4167479 | 1.00 | LCK (0.72) | LCKAPPCA12CA1CA2 | |
| (E)-3,4'-Stilbendiol SCHEMBL29798835 | 1.00 | LCK (0.72) | LCKAPPCA12CA1CA2 | |
| SCHEMBL482286 | 0.91 | CCNB2 (0.66) | LCKAPPCA12CA1CA2 | |
| SCHEMBL1931278 | 0.91 | APP (0.73) | LCKAPPCA12CA1CA2 | |
| SCHEMBL13338339 | 0.91 | LCK (0.86) | LCKAPPCA12CA2CA5A | |
| SCHEMBL2512336 | 0.91 | LCK (0.86) | LCKAPPCA12CA2CA5A | |
| SCHEMBL2512334 | 0.91 | LCK (0.86) | LCKAPPCA12CA2CA5A | |
| (E)-3-Stilbenol SCHEMBL5489745 | 0.88 | LCK (0.75) | LCKAPPKDM4EMEN1ALDH1A1 | |
| (E)-3-Stilbenol SCHEMBL113159 | 0.88 | LCK (0.75) | LCKAPPKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704801-A1 | COMPOSITIONS COMPRISING NIACINAMIDE AND RESVERATROL SALICYLATE | ELC Management LLC (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024229025-A1 | COMPOSITIONS COMPRISING NIACINAMIDE AND RESVERATROL SALICYLATE | ELC MANAGEMENT LLC (US) | 2024-11-07 | — | — | WO | claimed |
| CN-109516899-B | Preparation method of high-purity resveratrol | 杭州瑞树生化有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-112245371-A | Cosmetic with freckle removing and whitening functions and preparation method thereof | 杨萍萍 | 2021-01-22 | — | — | CN | claimed |
| US-10723834-B1 | Low melting and low viscosity thermoset matrix resins from the Z configuration of polyhydroxy stilbenes | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2020-07-28 | — | — | US | claimed |
| EP-4704801-A1 | COMPOSITIONS COMPRISING NIACINAMIDE AND RESVERATROL SALICYLATE | ELC Management LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-116034099-B | Solubilization of resveratrol glycolate and tartrate derivatives | ELC 管理有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2024229025-A1 | COMPOSITIONS COMPRISING NIACINAMIDE AND RESVERATROL SALICYLATE | ELC MANAGEMENT LLC (US) | 2024-11-07 | — | — | WO | disclosed |
| US-12042523-B2 | Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof | UNIGEN, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117224593-A | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | 尤尼根公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3212754-B1 | METHOD OF PRESERVING WINE AND PRESERVED RED WINE | RESWINE LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2010085851-A1 | MOLECULARLY IMPRINTED POLYMERS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-08-05 | — | — | WO | disclosed |
| US-20090175803-A1 | METHOD AND COMPOSITIONS FOR ADMINISTERING RESVERATROL AND PTEROSTILBENE | RUBIN DAVID | 2009-07-09 | — | — | US | disclosed |
| US-20090175984-A1 | METHOD AND COMPOSITIONS FOR PRESERVING WINE | Reswine, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20040259815-A1 | Anti-proliferative composition | GENERAL NUTRITION INVESTMENT COMPANY | 2004-12-23 | — | — | US | disclosed |
| EP-1448232-A1 | ANTI-PROLIFERATIVE COMPOSITION | N.V. Nutricia (NL) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043658-A1 | ANTI-PROLIFERATIVE COMPOSITION | N.V. NUTRICIA (NL) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314438-A1 | Anti-proliferative composition | Nutricia N.V. (NL) | 2003-05-28 | — | — | EP | disclosed |
| US-4654412-A | UNSATURATED MONOMERS, FIBERS, FILMS, MOLDINGS | CELANESE CORPORATION (US) | 1987-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042523-B2 | Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof | MATR3, ACACA, COL2A1 | LCK 4522/4885APP 3999/4885CA12 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.